AMA presses insurers to include new obesity meds in coverage

GLP-1 agonists are transforming the way cardiometabolic disorders are treated, with new approvals in obesity opening the door to significant new treatment opportunities.

With Denmark’s Novo Nordisk (NOV: N)  struggling to maintain supplies of its Wegovy (semaglutide), and rival Eli Lilly (NYSE: LLY) now offering its Mounjaro (tirzepatide) for obesity too under the trade name Zepbound, the level of demand is clear, but some are concerned that access may be limited.

In a statement, the American Medical Association (AMA) said insurance coverage barriers could prevent broad accessibility of these treatments.